enGene (NASDAQ:ENGN) Upgraded at Piper Sandler

Piper Sandler upgraded shares of enGene (NASDAQ:ENGN) from a neutral rating to an overweight rating in a research note released on Thursday morning, MarketBeat Ratings reports. Piper Sandler currently has $4.00 price target on the stock.

A number of other research analysts have also issued reports on the stock. Citigroup lowered shares of enGene from a “market perform” rating to a “hold” rating in a research note on Friday, October 16th. HC Wainwright reissued a “buy” rating on shares of enGene in a research report on Friday, October 16th. Jefferies Financial Group upgraded shares of enGene to a “strong-buy” rating in a report on Tuesday, October 13th. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, enGene presently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

enGene Stock Up 5.7%

Shares of NASDAQ ENGN traded up $0.13 during trading hours on Thursday, hitting $2.41. The stock had a trading volume of 3,704,347 shares, compared to its average volume of 1,532,640. The company has a market capitalization of $161.52 million, a P/E ratio of -1.16 and a beta of -0.24. The firm’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $3.97. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Analysts anticipate that enGene will post -1.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. SR One Capital Management LP bought a new stake in enGene in the second quarter valued at about $1,293,607. Eversept Partners LP grew its holdings in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after buying an additional 54,708 shares during the period. Renaissance Technologies LLC grew its holdings in shares of enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after buying an additional 135,318 shares during the period. Siren L.L.C. increased its position in shares of enGene by 57.5% in the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after buying an additional 1,916,895 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in shares of enGene in the 1st quarter valued at $409,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.